医学
HBeAg
丙氨酸转氨酶
慢性肝炎
肝活检
乙型肝炎病毒
内科学
纤维化
胃肠病学
炎症
抗病毒治疗
病毒
乙型肝炎
免疫学
活检
乙型肝炎表面抗原
作者
Qiuju Sheng,Ning Wang,Chong Zhang,Yaoxin Fan,Yanwei Li,Chao Han,Ziyi Wang,Shuqi Wei,Xiaoguang Dou,Yang Ding
出处
期刊:Journal of clinical and translational hepatology
[Xia & He Publishing]
日期:2022-03-17
卷期号:10 (5): 972-978
被引量:7
标识
DOI:10.14218/jcth.2021.00443
摘要
Alanine aminotransferase (ALT) is a common clinical indicator of liver inflammation. The current Chinese guidelines for the management of chronic hepatitis B (CHB) recommend antiviral treatment for patients with detectable hepatitis B virus (HBV) DNA and persistent ALT levels (ALTs) exceeding the upper limit of normal. However, it has been recently reported that patients with chronic HBV infection, especially HBeAg-negative patients with persistently normal ALTs, may have liver biopsy findings of significant inflammation and fibrosis. For HBeAg-negative patients with chronic HBV infection and normal ALTs, many controversial questions have been asked. To treat or not? When to initiate the treatment? Which drug is appropriate? In this review, we summarize the available data on the management of HBeAg-negative patients with chronic HBV infection and normal ALTs with the aim of improving the current clinical management.
科研通智能强力驱动
Strongly Powered by AbleSci AI